Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Artivion’s FDA updates, clinical-trial costs, and global device revenues can feel overwhelming when each SEC report stretches well past 200 pages. Whether you are tracking new aortic stent graft approvals or trying to spot shifts in mechanical heart-valve demand, the technical language in an Artivion annual report 10-K or a fresh 10-Q quarterly earnings report often masks the insights that drive decisions.
Stock Titan solves this problem. Our AI engine turns every filing into plain-English takeaways—Artivion SEC filings explained simply. Get instant alerts the moment an Artivion 8-K material event lands on EDGAR, skim AI-generated risk highlights, or drill straight into segment revenue tables without sifting through footnotes. Need to monitor management’s sentiment? Real-time dashboards surface Artivion Form 4 insider transactions so you can gauge executive conviction ahead of pivotal FDA milestones.
The platform covers every document type investors ask about:
- 10-K sections on product liability and clinical data—already summarized and compared year-over-year.
- 10-Q snapshots for revenue growth by valve, graft, and adhesive lines—ideal for quick Artivion earnings report filing analysis.
- 8-K event briefs that explain recall notices or trial results in minutes.
- Proxy statements outlining Artivion executive compensation and option grants.
- Form 4 dashboards showing Artivion insider trading Form 4 transactions in real time.
AORT filed a Form 144 indicating an intended sale of restricted or control securities. The filing covers a planned sale of 6,394 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $288,816.98. These shares are part of a class with 47,374,939 shares outstanding, and the approximate sale date is 11/17/2025 on the NYSE.
The seller acquired these shares on 11/17/2025 through an option granted on 03/05/2019, paid in cash. Over the prior three months, John E. Davis reported additional sales of common shares: 3,373 shares on 11/10/2025 for $150,499.55, 6,563 shares on 11/13/2025 for $300,968.02, and 6,393 shares on 11/14/2025 for $285,575.31.
AORT received a Form 144 notice indicating that Amy D. Horton plans to sell 6,000 shares of common stock through Fidelity Brokerage Services on the NYSE, with an approximate sale date of 11/17/2025. The filing notes that there were 47,374,939 common shares outstanding at the time referenced in the form.
The shares to be sold were originally acquired via restricted stock vesting from the issuer as compensation in February 2017, in two grants of 3,491 and 2,509 shares. Over the past three months, the seller has already sold 1,789 and 3,482 common shares, generating gross proceeds of $79,823.21 and $159,678.60, respectively.
Artivion, Inc. (AORT)6,394 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $288,816.98. These shares were acquired on 11/17/2025 through the cash exercise of an employee stock option originally granted on 03/05/2019. The filing notes that 47,374,939 common shares were outstanding. Over the prior three months, the same seller, Jean F. Holloway, reported selling additional common shares in three transactions totaling 22,154 shares for gross proceeds of $1,013,674.66.
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. filed an amended Schedule 13G reporting beneficial ownership of 2,020,000 shares of Artivion, Inc. (AORT) common stock, representing 4.3% of the class. The percentage is based on 47,374,939 shares outstanding as of October 31, 2025, as disclosed by the company.
The filers report shared voting power and shared dispositive power over 2,020,000 shares, with no sole voting or dispositive power. They certify the holdings were not acquired to change or influence control of Artivion.
AORT filed a Form 144 notice for a proposed sale of up to 6,393 shares of common stock with an aggregate market value of $287,685.00. The filing lists Fidelity Brokerage Services LLC as broker, an approximate sale date of 11/14/2025, and the NYSE as the exchange.
The seller previously completed several sales in the past three months: 10,000 shares on 11/11/2025 for $461,800.00, 5,761 shares on 11/13/2025 for $264,189.66, and 2,960 shares on 11/10/2025 for $132,071.94. Shares outstanding were 47,374,939.
Artivion (AORT) disclosed an insider transaction by its VP, Chief Accounting Officer. On 11/13/2025, the officer sold 3,482 shares of common stock at $45.858 per share. According to the filing, the sale was executed to cover tax withholding triggered by the vesting of restricted stock units and “does not represent a discretionary transaction.”
Following this sell-to-cover transaction, the officer beneficially owned 141,380 shares, held directly.
Artivion, Inc. (AORT) reported an insider Form 4. The Chief Commercial Officer sold 6,563 shares of common stock at $45.858 on 11/13/2025 (Transaction code: S). According to the footnote, the shares were sold upon RSU vesting to cover tax withholding via a “sell to cover” and do not represent a discretionary transaction.
After the sale, the reporting person beneficially owned 198,842 shares, held directly.
Artivion, Inc. (AORT) President & CEO James P. Mackin reported a Form 4 transaction: the sale of 34,210 shares of common stock at $45.858 on November 13, 2025. The filing states the shares were sold upon RSU vesting to satisfy tax withholding via a “sell to cover” and did not represent a discretionary transaction.
Following the sale, Mackin beneficially owned 800,993 shares, held directly. The transaction code was S, reflecting an open-market or private sale executed to cover withholding obligations tied to equity compensation vesting.
Artivion, Inc. (AORT) insider transaction: SVP and General Counsel Jean F. Holloway reported the sale of 5,761 shares of common stock at $45.858 on 11/13/2025. The filing states the shares were sold upon the vesting of restricted stock units to pay tax withholding obligations via a “sell to cover” and “does not represent a discretionary transaction.”
Following the sale, the reporting person beneficially owns 163,408 shares directly. This Form 4 reflects an administrative tax-related sale rather than an open‑market discretionary trade.
Artivion (AORT) insider transaction: Officer Marshall Stanton reported a sell-to-cover of 4,993 shares of common stock at $45.858 on 11/13/2025. The filing states the shares were sold upon RSU vesting to satisfy tax withholding obligations and did not represent a discretionary transaction.
Following the transaction, Stanton beneficially owns 56,641 shares directly. His role is listed as SVP, Clinical & MD Affair, and the filing was made by one reporting person.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
